Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs.
BACKGROUND
Cancer cachexia, a catabolic state characterized by weight loss, occurs frequently in patients with terminal-stage neoplastic diseases. Gastrointestinal hormones and cytokines may be associated with anorexia and wasting in cancer cachexia.


METHODS
This study aimed to examine the mechanism of anorexia in cachectic patients through a prospective investigation of plasma cytokines, ghrelin, and leptin in 16 cachectic patients with cancer of the digestive organs and 10 healthy volunteers.


RESULTS
Tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-1 receptor antagonist (IL-1Ra), and ghrelin levels were significantly higher in cachectic cancer patients than in the healthy volunteers, whereas leptin was significantly lower in the cachectic cancer patients. Plasma leptin levels and cytokine levels (TNF-alpha and IL-6) correlated significantly with body mass index (BMI), but plasma ghrelin levels did not correlate with BMI or with the grade of symptoms.


CONCLUSIONS
Neither weight loss nor the grade of symptoms seemed to be directly associated with the increase in ghrelin levels. Hence, it is considered that the increase in ghrelin levels cannot simply be explained by an increase in ghrelin secretion, suggesting that other mechanisms, such as the decreased inactivation of ghrelin, may also play a role. Further studies are needed to clarify the mechanisms of the increase in ghrelin levels. Additionally, the changes in plasma cytokines (TNF-alpha and IL-6) and leptin in cachectic cancer patients suggest that these molecules may be useful markers for the evaluation of cancer cachexia.
Takahashi
Masanori
M
Department of Surgery, Iwate Medical University, Morioka, Japan.
Terashima
Masanori
M
Takagane
Akinori
A
Oyama
Kenichi
K
Fujiwara
Hisataka
H
Wakabayashi
Go
G
D000368:Aged; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002100:Cachexia / Q000097:blood / Q000209:etiology*; D016022:Case-Control Studies; D015536:Down-Regulation; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000097:blood / Q000150:complications*; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D015854:Up-Regulation
D015415:Biomarkers; C515349:GHRL protein, human; D054439:Ghrelin; C507763:IL1RN protein, human; C508600:IL6 protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6; D020738:Leptin; D014409:Tumor Necrosis Factor-alpha
Biochem Biophys Res Commun. 2003 Feb 7;301(2):275-9
12565855
J Clin Endocrinol Metab. 2001 Jan;86(1):162-6
11231995
Clin Cancer Res. 2003 Feb;9(2):774-8
12576449
N Engl J Med. 2002 May 23;346(21):1623-30
12023994
J Mol Med (Berl). 2000;78(10):554-61
11199328
J Clin Endocrinol Metab. 2004 Jun;89(6):2832-6
15181065
Nature. 2000 Oct 19;407(6806):908-13
11057670
Cytokine. 2002 Jul 7;19(1):21-6
12200109
J Clin Endocrinol Metab. 2004 Nov;89(11):5392-6
15531487
Gastroenterology. 2001 Feb;120(2):337-45
11159873
Clin Chem. 2004 Sep;50(9):1511-25
15265818
Nature. 1999 Dec 9;402(6762):656-60
10604470
Cancer. 2006 Feb 15;106(4):966-73
16411208
J Clin Invest. 2004 Jul;114(1):57-66
15232612
Curr Pain Headache Rep. 2001 Jun;5(3):250-6
11309213
Metabolism. 2004 Jan;53(1):84-8
14681847
Semin Oncol. 1998 Apr;25(2 Suppl 6):45-52
9625383
J Clin Endocrinol Metab. 2005 May;90(5):2920-6
15713718
Surg Today. 1996;26(7):467-75
8840426
Nature. 1994 Dec 1;372(6505):425-32
7984236
Support Care Cancer. 1993 Nov;1(6):290-4
8156245
Clin Endocrinol (Oxf). 2002 Jun;56(6):723-33
12072041
Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):277-89
14561193
Nat Rev Neurosci. 2001 Aug;2(8):551-60
11483998
Cancer. 2003 Mar 1;97(5):1211-6
12599227
Clin Sci (Lond). 1997 Sep;93(3):273-7
9337643
Circulation. 2004 May 11;109(18):2221-6
15117840